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Purpose: To evaluate the efficacy, effect profile, and safety of dexamethasone implant on diabetic macular
edema (DME) in a real-life setting, further comparing results by DME duration, previous treatment status, and
diabetic control.
Design: A multicenter, retrospective cohort of 340 DME eyes of 287 patients from 25 clinical sites from 8
countries.
Methods: Data were analyzed in 2 perspectives: per injection, in which all measurements were grouped and
baseline was defined as the day of injection, and thus the pharmacodynamics of single injections could be
assessed; and injection series, defined as 2 or more injections with 3 to 6 months between injections analyzing
the outcome 3 to 6 months after the last injection.
Main Outcome Measures: Primary outcome was improvement of 15 or more letters in best-corrected visual
acuity (BCVA) from baseline. Secondary outcomes included improvement of 10 letters or more in BCVA, change
in central macular thickness (CMT), and time to maximum improvement and safety.
Results: Overall, 762 injections were administered to 340 eyes of 287 patients. Injection series analysis
included 171 series in 171 eyes of 150 patients, for a total of 444 injections, with a mean follow-up of 1.70.8
years. Of the 762 injections analyzed per injection, 22.7% achieved a 15-letter or more improvement, and 37.8%
achieved a 10-letter or more improvement. Mean time to peak improvement was 81.939.7 days. Mean
maximum change in CMT was e174171 mm. Overall, 7.6% lost 15 or more letters. More eyes with early DME
gained 10 or more letters and fewer eyes lost 10 or more letters compared with eyes with late DME (47.4% vs.
33.9% [P ¼ 0.001] and 8.2% vs. 13.5% [P ¼ 0.029], respectively). Patients with controlled diabetes showed
greater CMT reduction (P ¼ 0.0002). A higher percentage of treatment-naive patients gained 10 or 15 letter or
more in BCVA (P ¼ 0.001 and P ¼ 0.006, respectively). Intraocular pressure elevation of more than 25 mmHg was
found following 7.9% of injections; no endophthalmitis was reported.
Conclusions: Dexamethasone implant is an effective and safe treatment for DME. Peak improvement was
achieved 3 months after injection and dissipated thereafter. Clinicians and providers may consider shortening
treatment intervals. Ophthalmology 2019;-:1e17 ª 2019 by the American Academy of Ophthalmology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Supplemental material available at www.aaojournal.org.Diabetic macular edema (DME) is one of the leading causes
of visual loss among working-age patients (20e65 years)
and the elderly.1 It is estimated to affect 20% of patients
with diabetic retinopathy,2 and its prevalence increases
with that of diabetes.3,4 Diabetic macular edema is a
multifactorial disease, driven by proinflammatory andª 2019 by the American Academy of Ophthalmology
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(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.proangiogenic elements.5 It is characterized by macular
thickening secondary to capillary leakage and fluid
accumulation.6 Antievascular endothelial growth factor
(VEGF) therapies have been proven effective, leading to
improved visual acuity and macular thickness reduction.7
However, according to post hoc analysis of the Diabetic1https://doi.org/10.1016/j.ophtha.2019.10.005
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Ophthalmology Volume -, Number -, Month 2019Retinopathy Clinical Research Network trials, a significant
percentage of patients do not show a sufficient initial
response to this treatment or do not reach complete
anatomic resolution8e10; hence, a need for alternative ther-
apy exists. In addition, current anti-VEGF treatments require
frequent injections and monitoring, causing a significant
burden on patients and health care systems, with a financial
impact and reduction in patient quality of life.11 Laser
photocoagulation may prevent visual acuity loss in certain
groups of patients; however, it typically cannot restore or
improve visual acuity and is inferior to anti-VEGF
treatments.12
Corticosteroids inhibit leukocytosis and expression of
prostaglandins and proinflammatory cytokines, enhance the
barrier function of vascular tight junctions, and reduce
VEGF levels.13 Therefore, intravitreal corticosteroids may
play an important role as an alternative treatment for
DME. Injections of triamcinolone have been used
commonly; however, these treatments are associated with
significant adverse events (AEs), primarily intraocular
pressure (IOP) elevation and cataract formation.12
The dexamethasone intravitreal implant (Ozurdex;
Allergan, Inc., Irvine, CA) is a sustained-release biode-
gradable implant injected into the vitreous that delivers 0.7
mg dexamethasone to the posterior segment of the eye. The
biodegradable implant has dual-phase pharmacokinetics,
initially releasing a burst of dexamethasone to achieve a
rapidly therapeutic concentration followed by a lower sus-
tained release.14,15
The results of the 3-year multicenter, phase 3 randomized
clinical trials from the Macular Edema: Assessment of
Implantable Dexamethasone in Diabetes (MEAD) study
group demonstrated that the dexamethasone intravitreal
implant is an effective treatment method for DME, with
approximately 20% of patients achieving a visual acuity
improvement of 15 Early Treatment Diabetic Retinopathy
Study (ETDRS) letters sustained with repeated injections
over 3 years.16 Although this study showed that the
dexamethasone intravitreal implant is an effective and safe
treatment, treated eyes demonstrated a distinct pendular
effect of improvement and deterioration throughout the 6-
month mandatory interval between injections. Based on
these results, the dexamethasone intravitreal implant has
been approved for treatment every 6 months by the Food
and Drug Administration and European Medicine Agency
for DME in pseudophakic eyes and as a second-line treat-
ment to nonresponsive phakic eyes. Querques et al17
emphasized the need for a study to evaluate the optimal
dexamethasone treatment frequency in patients with DME.
To date, several studies have been published on the use of
the dexamethasone intravitreal implant in real-life settings,
and although some were relatively small,18e21 others
included a large cohort and a good design. Nevertheless,
these studies concentrated on its effect on the entire cohort
or assessed the effect comparing a single subgroup.22e24
Because the real-life optimal treatment interval between
the dexamethasone intravitreal implant injections is debatable
and is heavily dependent on clinical response to each treat-
ment rather than a preset interval, we recognized 2 unmet2
needs with regard to the study of the therapeutic effect of the
dexamethasone intravitreal implant, the first of which is the
lack of an in-depth analysis and depiction of the actual ther-
apeutic profile of each implant within an injection series,
allowing for a better understanding and planning of treatment
frequency and follow-up protocols. The second is that pre-
vious studies allowed for the inclusion of patients treated at
variable and relatively long intervals, thus introducing po-
tential confounders for the treatment effect. Therefore, a need
arose for a study to evaluate the effect an injection series with
strict interval limitations. To the best of our knowledge, no
study to date has examined and characterized the effect profile
of the dexamethasone intravitreal implant injection. In addi-
tion, we aimed to address the difference in treatment effect
between early and late DME, treatment-naive and previously
treated eyes, and patients with controlled and uncontrolled
diabetes in a large, international, multicenter, real-life study.
The purpose of the current study was to evaluate the phar-
macodynamics and clinical and anatomic effects over time of
each dexamethasone intravitreal implant injection as well as
the efficacy and safety of a dexamethasone intravitreal
implant injection series with strict interval limitations within a
real-life setting.
Methods
This study was approved by the independent ethics committee or
institutional review board of the clinical sites where the study was
conducted, or by another relevant ethics committee. No informed
consent was needed. This study also was designed, implemented,
and reported in accordance with the International Council for
Harmonisation (ICH) Tripartite Guidelines for Good Clinical
Practice, with applicable local regulations such as European
Directive 2001/20/EC, and with the ethical principles laid down in
the Declaration of Helsinki.
Study Design and Population
This multicenter retrospective cohort included DME patients from
25 European Vision Clinical Research Network clinical sites from
8 countries in Europe and Israel. Consecutive patients older than 18
years with type 1 or 2 diabetes and DME with central macular
thickness (CMT) of 300 mm or more were included in the study.
All patients demonstrated a minimum best-corrected visual acuity
(BCVA) of 20/200 (35 ETDRS letters) at baseline. Patients with
additional ophthalmic comorbidities that may affect BCVA, such
as patients with any history of advanced age-related macular
degeneration, retinal vein occlusion, proliferative diabetic reti-
nopathy, glaucoma, or ocular hypertension (defined as IOP >23
mmHg without antiglaucoma medication, IOP >21 mmHg with 1
medication, or any use of 2 or more medications), optic neuropa-
thy, or corneal opacity, were excluded. Also excluded were pa-
tients with previous ocular trauma or any surgery other than
cataract extraction or steroid responders. Patients with DME who
had undergone intravitreal triamcinolone 6 months or less before
baseline or intravitreal bevacizumab, ranibizumab, or aflibercept 1
month or less before baseline were excluded as well.
Data Collection
Data were collected by retrospective review of the patients’ med-
ical charts and entered using electronic case report forms. Collected
Table 1. Baseline Characteristics of Patients and Study Eyes for All Injections
Overall (287 Patients; 340 Eyes) Injection Series (150 Patients; 171 Eyes)
Age (yrs)
Mean  SD 66.299.33 65.268.58
Range 24.00e89.00 24.00e89.00
Male gender, no. (%) 183 (63.8) 94 (62.7)
ETDRS letter score, mean  SD 61.913.5 57.4613.11
CMT (mm), mean  SD 498139 519.2152.7
IOP (mmHg), mean  SD 15.652.78 15.682.77
Use of IOP-lowering medication, no. (%) 53 (18.5) 31 (20.7)
Mean duration of diabetes (yrs), mean  SD 14.169.54 14.439.04
Mean HbA1c (%), mean  SD* 7.691.18 7.671.21
8%, no. (%) 151 (52.6) 83 (55.3)
>8%, no. (%) 88 (30.7) 44 (29.3)
Not available, no. (%) 48 (16.7) 23 (15.3)
Mean duration of DME (mos), mean  SD 24.328.8 27.032.1
Range (mos) 0e163 0e163
Less than 6 mos, no. (%) 100 (29.4) 40 (23.4)
More than 6 mos, no. (%) 201 (59.1) 114 (66.7)
Unknown 39 (11.5) 17 (9.9)
Previous treatment for DME, no. (%)y 221 (65.0) 118 (69.0)
Focal/grid laser 185 (83.7) 98 (83.1)
Intravitreal steroid 39 (17.6) 18 (15.3)
Anti-VEGF 208 (94.1) 96 (81.4)
None 119 (35.0) 53 (31.0)
DME perfusion status, no. (%)
Ischemic 84 (24.7) 52 (30.4)
Nonischemic 256 (75.3) 119 (69.6)
Lens status, no. (%)
Phakic 205 (60.3) 109 (63.7)
Pseudophakic 135 (39.7) 62 (36.3)
CMT ¼ central macular thickness; DME ¼ diabetic macular edema; ETDRS ¼ Early Treatment Diabetic Retinopathy Study; HbA1c ¼ hemoglobin A1c;
IOP ¼ intraocular pressure; SD ¼ standard deviation; VEGF ¼ vascular endothelial growth factor.
*Based on number of patients.
yPatients could have multiple treatment types.
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history, type of DME, number and dates of the dexamethasone
intravitreal implant injections, additional treatments for DME
(before and after dexamethasone intravitreal implant administra-
tion), BCVA and IOP throughout the study period, cataract pro-
gression throughout the study period, and the occurrence of any
complications. All IOP measurements were measured by Goldman
applanator tonometer. All visual acuity measurements were
measured using Snellen charts and later were converted into log-
arithm of the minimum angle of resolution for statistical analysis.
Data regarding CMT and presence of intraretinal fluid from OCT
scans were collected. The electronic case report form was designed
with built-in edit checks that prompted the users for immediate data
verification before committing data to the database. This measure
was introduced to reduce typos and data entry errors.
Data Analysis
Analysis by Series. All patients included in the analysis received a
minimum of 2 dexamethasone intravitreal implants with an interval
of 3 to 6 months (2 weeks) between injections and at least 3
months of follow-up after the last injection that met the inclusion
criteria. Treatment outcome was defined as the change from the day
of first injection to the result of last injection up to 6 months after
the last injection.
Analysis by Injection. This analysis included all visual and
anatomic observations of each study patient in the 6 months after
each injection received (including those who were not included inthe analysis per series because of injection intervals of more than 6
months or a single injection being received). The data were
analyzed and displayed to depict the change over time in study
outcomes up to 6 months after any injection. All analyses were
performed for the entire cohort and by predefined subgroups (Fig
S1, available at www.aaojournal.org). Contrary to the per-series
analysis, in which the effect of a series of injections was
analyzed for patients treated at defined intervals, the purpose of the
analysis per injection was to study the effect of any injection on the
visual and anatomic outcomes and to characterize the pharmaco-
dynamics of the dexamethasone intravitreal implant. The summa-
tion of data from all study patients at all follow-up points allows
better definition of the response over time to any injection (and
later conclusions regarding optimal dosing intervals) while avoid-
ing underrepresentation of eyes treated with a single injection
because of poor response or loss to follow-up.
Predefined Subgroup Analysis. Three comparisons were made
between subgroups: previous treatment status, comparing treatment-
naive patients with previously treated patients conditioned on the
patientsmeeting the inclusion criteria regarding interval fromprevious
treatment: duration of DME, comparing early DME (defined as less
than 6months documentedDME) and late DME (defined as 6months
or more of documented DME); and measure of diabetic control,
defined similarly to the MEAD tables, that is, comparing controlled
diabetes (defined as a blood level of hemoglobin A1c [HbA1c] lower
than 8mg/100) versus uncontrolled diabetes (defined as blood level of
HbA1c of 8 mg/100 or more).163
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SD ¼ standard deviation.
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The primary outcome was defined as percentage of patients with
improvement of 15 or more ETDRS letters of BCVA from baseline
3 to 6 months after the dexamethasone intravitreal implant injec-
tion or after the last injection. The secondary outcomes were
improvement of 10 or more ETDRS letters of BCVA from base-
line, time to BCVA improvement of 15 or more or 10 ETDRS
letters or more, change in CMT from baseline during the study, and
the percentage of patients with BCVA reduction of 10 or more
ETDRS letters or more than 15 ETDRS letters from baseline and
safety. Decrease in visual acuity was defined as a decrease in
BCVA without a prior increase of at least 5 ETDRS letters after an
injection. Safety measures included description of the percent of
patients demonstrating cataract formation or progression, cataract
operation, absolute IOP and IOP elevation of more than 10 mmHg,
use of IOP-lowering medications, and other AEs.
Statistical Analysis
The data were analyzed using SAS software version 9.3 (SAS
Institute, Cary, NC). All measured variables and derived parame-
ters were tabulated by descriptive statistics. For categorical vari-
ables, summary tables were provided, giving sample size and
absolute and relative frequency by individual treatment groups. For
continuous variables, summary tables were provided giving sample
size, arithmetic mean, standard deviation, minimum, median, and4
maximum by individual treatment groups. Analyzed groups for the
tables included HbA1c status, DME duration, and DME status.
Changes from baseline for ETDRS and CMT were tabulated per
group. Differences were tested using independent sample t tests.
The number of injections resulting in an increase of 10 or 15
ETDRS letters or a decrease of 10 or 15 ETDRS letters was
tabulated by the number of frequency of participants. The differ-
ence between groups was analyzed using the chi-square test.
Snellen values were converted to ETDRS letters. A 2-sided P value
of less than 0.05 was considered statistically significant.
Results
The study included 340 eyes of 287 patients who received a total of
762 injections. Thirty-six percent of patients were women, and the
mean age was 66.39.3 years. Of the 340 eyes, 171 (50.2%)
received multiple injections meeting the criteria for an injection
series. No eyes met the criteria twice; thus, no sequential injection
series was included in the analysis.
Baseline Characteristics
Table 1 depicts the baseline characteristics of the per-injection and
per-series analyses, respectively. In the per-injection analysis,
mean baseline BCVA was 58.1 ETDRS letters (Snellen equivalent,
approximately 20/80), mean CMT was 495.2137.4 mm, and
mean duration of DME before study entry was 24.3 months. For
the per-series analysis, 171 eyes of 150 patients met the criteria of a
continuous injection series, mean BCVA was 56.5 ETDRS letters
(Snellen equivalent, approximately 20/80), mean CMT was
533154 mm, and mean duration of DME before study entry was
24.3 months.
Per-Injection Analysis
Entire Cohort. Overall, this analysis includes the data from 2192
observation points of 762 injections per eye in 340 eyes throughout
the study; mean number of injections per eye was 2.241.11 in-
jection per patient (range, 2e8; Table 2). Of the 762 injections
administered, 173 (22.7%) and 288 (37.8%) resulted in
improvement of 15 and 10 ETDRS letters or more of BCVA
improvement from baseline, respectively, whereas 58 eyes
(7.6%) experienced reduction of more than 15 ETDRS letters in
BCVA, and 95 eyes (12.5%) experienced a reduction of 10 or
more ETDRS letters. The mean time to peak improvement after
an injection was 81.939.7 days, and the mean change in CMT
was e174171 mm. Immediately after the injection, a
statistically significant anatomic improvement became evident
that was maintained throughout the first 3 months, with the
effect later diminishing but remaining significantly improved at 6
months (Fig 1). Similarly, a significant improvement in visual
acuity (with a slight delay compared with reduction in CMT)
became evident that diminished after 3 months yet remained
significant at 6 months (Fig 2).
Treatment-Naive versus Previously Treated Patients. Of the
762 injections included in this analysis, 243 injections were
administered to 119 treatment-naive eyes, and 519 injections were
administered to 221 previously treated eyes. At baseline, mean
BCVA was significantly better in the treatment-naive eyes
compared with the previously treated eyes (66.811.3 ETDRS
letters vs. 59.613.9 ETDRS letters, respectively; P < 0.0001),
whereas there was no significant difference in CMT (P ¼ 0.101).
After an injection, a significantly greater percentage of treatment-
naive eyes gained 15 or more ETDRS letters of BCVA (70 eyes
[28.8%]) compared with previously treated eyes (103 eyes
[19.8%]; P ¼ 0.006). One hundred twelve injections (46.1%) to
Figure 1. Graph showing anatomic changes after a dexamethasone implant injection, entire cohort (per-injection analysis). CMT ¼ central macular
thickness; SE ¼ standard error.
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more of BCVA compared with 176 injections (33.9%) in previ-
ously treated patients (P ¼ 0.001). Overall, mean change in BCVA
was slightly better in treatment-naive eyes compared with the
previously treated patients (8.112.5 ETDRS letters vs. 6.210.4
ETDRS letters, respectively), yet this difference was not statisti-
cally significant (P ¼ 0.073). Mean change in CMT did not differ
between the 2 groups (P ¼ 0.620). No statistically significant
difference was found comparing the time to 15-letter improvement
from baseline, time to 10-letter improvement from baseline, time to
10-letter reduction from baseline, time to 15-letter reduction from
baseline, time to peak improvement in BCVA from baseline, time
to peak improvement in CMT from baseline, number of injections,
or duration in study. Further comparisons and details are described
in Table 3. No significant anatomic differences emerged over time
between treatment-naive and previously treated eyes (Fig 3);
however, a lower amplitude of visual improvement was apparent
in previously treated patients (Fig 4).
Early versus Late Diabetic Macular Edema (Duration <6
Months vs. ‡6 Months). The study included 196 injections given
to 100 eyes of patients with early DME, 466 injections to 200 eyes
of patients with late DME, and 100 injections to 39 patients with an
unknown duration of DME. The mean baseline visual acuity was
significantly lower for late DME patients compared with patients
with an earlier onset of disease (65.012.6 ETDRS letters vs.
62.012.4 ETDRS letters, respectively; P ¼ 0.008). There was anonsignificant trend toward a higher proportion of 15-letter or more
improvement in the early DME group (26.5% vs. 20.0%;
P ¼ 0.06), whereas the difference for 10-letter or more gain was
significant (47.4% vs. 33.9%; P ¼ 0.001). Significantly more eyes
lost 10 ETDRS letters or more in the late DME group (13.4% vs.
8.2%; P ¼ 0.029), and no difference was found in the percentage
of injections resulting in a reduction of 15 ETDRS letters or more
(5.6% vs. 7.1%; P ¼ 0.383). Mean change in CMT after each
injection was e151171 mm versus e180173 mm in the early
and late DME patients, respectively (P ¼ 0.088). Time from in-
jection to peak improvement in CMT from baseline was slightly
shorter in patients with late DME (76.534.8 days) than in patients
with an early onset of disease (87.041.7 days; P ¼ 0.006). Time
to 15-letter improvement from baseline, time to 10-letter
improvement from baseline, time to 10-letter reduction from
baseline, time to 15-letter reduction from baseline, time to peak
improvement in BCVA from baseline, baseline CMT, change in
CMT from baseline, number of injections, and duration in study
did not differ significantly between the groups (Table 4). There was
no significant difference in CMT over time between early and late
DME patients (Fig 5), with a similar delay in visual improvement
as described previously (Fig 6), with the improvement in the late
DME patients not as pronounced and maintained for a shorter time.
Controlled versus Uncontrolled Diabetes (Hemoglobin A1c
<8 mg/100 vs. ‡8 mg/100). The study included 386 injections to
172 eyes of patients with controlled diabetes (HbA1c, 8%), 2485
Figure 2. Graph showing functional changes after a dexamethasone implant injection, entire cohort (per-injection analysis). ETDRS ¼ Early Treatment
Diabetic Retinopathy Study; SE ¼ standard error.
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(HbA1c, >8%), and 128 injections to 58 eyes of patients with an
unknown HbA1c level. At baseline, a significantly better BCVA
was found in the controlled disease group compared with the
uncontrolled diabetes (63.612.1 ETDRS letters vs. 60.615.2
ETDRS letters, respectively; P ¼ 0.014). The percentage of eyes
with BCVA improvement of 15 or more ETDRS letters at the end
of the dexamethasone intravitreal implant injection and the per-
centage of BCVA improvement of 10 or more ETDRS letters did
not differ significantly (24.4% vs. 20.2% [P ¼ 0.219] and 39.4%
vs. 35.5% [P ¼ 0.324], respectively). In contrast, the percentage of
eyes experiencing a reduction in visual acuity after the dexa-
methasone intravitreal implant injection was significantly larger in
patients with uncontrolled diabetes for both 10 ETDRS letters or
more (16.1% vs. 10.1%; P ¼ 0.023) and 15 ETDRS letters or
more (10.5% vs. 5.7%; P ¼ 0.025). The baseline CMT did not
differ significantly between the groups (P ¼ 0.182), yet there was
a greater reduction in controlled disease patients (e190178 mm
vs. e135145 mm; P ¼ 0.0002). Time to 15-letter improvement
from baseline, time to 10-letter improvement from baseline, time
to 10-letter reduction from baseline, time to 15-letter reduction
from baseline, time to peak improvement in BCVA from baseline,
time to peak improvement in CMT from baseline, number of in-
jections, and duration in study did not differ significantly between
controlled and uncontrolled diabetes patients. Further comparisons
and details are described in Table 5. No significant anatomic6
differences were evident over time between controlled and
uncontrolled patients (Fig 7); however, a lower amplitude of
visual improvement was evident in uncontrolled patients (Fig 8).
Per-Series Analysis
Entire Cohort. In this analysis, we reviewed 171 eyes of 150
patients meeting the defined criteria for an injection series who
received a total of 444 injections with a mean of 2.601.0 in-
jections per series (range, 2e8; Table 2). An improvement of 15
and 10 ETDRS letters occurred in 20.5% (n ¼ 35) and 35.7%
(n ¼ 61), respectively, whereas 7.0% (n ¼ 12) lost more than 15
ETDRS letters in BCVA, and 12.3% (n ¼ 21) lost 10 ETDRS
letters in BCVA. Mean change in CMT was e151197 mm.
The dynamic in BCVA (Fig S2, available at
www.aaojournal.org) and CMT (Fig S3, available at
www.aaojournal.org) seen in the per-injection analysis clearly is
visible during the first 5 months; past this point, a smoothing effect
attributed to the variable interval allowed between injections is
apparent.
Treatment-Naive versus Previously Treated Patients. Of the
171 included in this analysis, 53 eyes had not been treated previ-
ously (i.e., were treatment naive), and 118 had been treated pre-
viously (Table S1A, available at www.aaojournal.org). At baseline,
mean BCVA was significantly better in the treatment-naive eyes
(59.413.2 ETDRS letters vs. 55.213.2 ETDRS letters;














Baseline BCVA (ETDRS letters), mean  SD 61.913.5 66.811.3 59.613.9 7.1694 5.2281 to 9.1108 <0.0001
Injections with 15-letter BCVA improvement
from baseline, no. (%)
173 (22.7) 70 (28.8) 103 (19.8) 0.6119 0.4305 to 0.8697 0.0059
Time to 15-letter improvement in BCVA from
baseline (days), mean  SD
81.339.2 77.736.0 83.841.3 e6.0241 e18.0195 to 5.9712 0.3229
Injections with 10-letter BCVA improvement
from baseline, no. (%)
288 (37.8) 112 (46.1) 176 (33.9) 0.6002 0.4398 to 0.8190 0.0012
Time to 10-letter improvement in BCVA from
baseline (days), mean  SD
66.111.3 68.89.8 64.411.8 0.7240 e8.4596 to 9.9076 0.8768
Injections with 10-letter BCVA reduction from
baseline, no. (%)
95 (12.5) 25 (10.3) 70 (13.5) 1.4171 0.8714 to 2.3046 0.1585
Time to 10-letter reduction in BCVA change
from baseline (days), mean  SD
96.644.3 91.042.1 98.645.1 e7.5600 e28.0868 to 12.9668 0.4664
Injections with 15-letter BCVA reduction from
baseline at study end, no. (%)
58 (7.6) 18 (7.4) 40 (7.7) 1.0833 0.6067 to 1.9343 0.7868
Time to 15-letter reduction in BCVA change
from baseline, mean  SD
96.545.3 92.446.8 98.345.1 e5.9361 e31.8891 to 20.0169 0.6486
Change in BCVA from baseline (ETDRS letters),
mean  SD
6.811.1 8.112.5 6.210.4 1.8948 e0.1745 to 3.9640 0.0726
Time to peak improvement in BCVA from
baseline (days)
81.939.7 82.840.1 81.539.6 1.2213 e5.6768 to 8.1194 0.7282
Baseline CMT (mm), mean  SD 498139 479128 508144 e28.7211 e63.0974 to 5.6553 0.1012
Change in CMT from baseline at study end (mm),
mean  SD
e174171 e157180 e182167 25.8578 e4.2757 to 55.9913 0.0925
Time to peak improvement in CMT from baseline
(days), mean  SD
79.638.1 83.139.2 78.137.5 5.3053 e1.3418 to 11.9523 0.1175
No. of injections, mean  SD 2.11.2 2.1  1.1 2.2  1.2 e0.1004 e0.2831 to 0.0824 0.2813
Duration (yrs) in study, mean  SD 1.80.8 1.9  0.9 1.8  0.8 0.1469 e0.0624 to 0.3562 0.1681
BCVA ¼ best-corrected visual acuity; CMT ¼ central macular thickness; ETDRS ¼ Early Treatment Diabetic Retinopathy Study; SD ¼ standard deviation.














Figure 3. Graph showing anatomic changes after a dexamethasone implant injection, stratified by treatment status (per-injection analysis). CMT ¼ central
macular thickness; SE ¼ standard error.
Ophthalmology Volume -, Number -, Month 2019P ¼ 0.026), and baseline CMT was similar (P ¼ 0.570). At the end
of an injection series, the treatment-naïve eyes showed a
significantly greater percentage with BCVA improvement of 15
ETDRS letters or more (34.0% vs. 14.4%, respectively; P ¼
0.003) and 10 ETDRS letters or more (49.1% vs. 29.7%,
respectively; P ¼ 0.003), as well as mean change in BCVA
(8.511.9 vs. 3.512.4, respectively; P ¼ 0.017). Statistically
significant differences also were found in the time to 15-letter
improvement from baseline (29392.4 days vs. 451242 days,
respectively; P ¼ 0.012), time to 10-letter improvement from
baseline (30496 days vs. 415211 days, respectively; P ¼
0.004), and time to peak change in BCVA (320104 days vs.
363163 days, respectively; P ¼ 0.044). The mean change in
CMT did not differ between the 2 groups (P ¼ 0.620. Similarly, no
statistically significant difference was found in the time to 10-letter
reduction from baseline, time to 15-letter reduction from baseline,
baseline CMT, number of injections, or duration in study.
Early versus Late Diabetic Macular Edema (Duration <6
Months vs. ‡6 Months). The study included 40 patients with
early DME, 114 eyes with late DME, and 17 eyes with an un-
known duration of DME. Baseline mean BCVA was similar in
both eyes with early and late DME (58.614.0 ETDRS letters vs.
57.112.1 ETDRS letters, respectively; P ¼ 0.470). Significantly
fewer early DME eyes showed a reduction of 15 ETDRS letters
(0% vs. 8.8%, respectively). No significant difference was
evident in early versus later DME in terms of percentage of eyes8
with improvement of 15 ETDRS letters (27.5% vs. 17.5%,
respectively; P ¼ 0.177), of 10 ETDRS letters (47.5% vs. 31.6%,
respectively; P ¼ 0.07), or reduction of 15 ETDRS letters and
reduction of 10 ETDRS letters (4.7% vs. 13.9%, respectively;
P ¼ 0.09). Mean change in CMT was e182196 mm versus
e144204 mm in the early and late DME patients, respectively
(P ¼ 0.354). Time to 15-letter improvement from baseline, time
to 10-letter improvement from baseline, time to 10-letter reduc-
tion from baseline, eyes with 15-letter reduction from baseline,
time to 15-letter reduction from baseline, time to peak
improvement in BCVA from baseline, baseline CMT, change in
CMT from baseline, time to peak improvement in CMT from
baseline, number of injections, and duration in study did not
differ significantly between the groups. Further comparisons and
details are described in Table S1B (available at
www.aaojournal.org).
Controlled versus Uncontrolled Diabetes (Hemoglobin A1c
<8 mg/100 vs. ‡8 mg/100). The study included 93 eyes of pa-
tients with controlled diabetes (HbA1c, 8%), 49 with eyes of
patients with uncontrolled diabetes (HbA1c, >8%), and 29 eyes of
patients with an unknown HbA1c level. At baseline, BCVA did not
defer significantly between the controlled and uncontrolled disease
groups (P ¼ 0.500). No significant difference was found in per-
centage of eyes with 15-letter or more improvement (20.4% vs.
20.4%, respectively; P ¼ 0.997), 10-letter or more improvement
(34.4% vs. 32.7%, respectively; P ¼ 0.833), reduction of 15
Figure 4. Graph showing functional changes after a dexamethasone implant injection, stratified by treatment status (per-injection analysis). ETDRS ¼
Early Treatment Diabetic Retinopathy Study; SE ¼ standard error.
Rosenblatt et al  The ARTES StudyETDRS letters (P ¼ 0.607), and reduction of 10 ETDRS letters
(P ¼ 0.803). Baseline CMT was significantly thicker in the
controlled disease group (549151 mm vs. 491167 mm; P ¼
0.01), and the respective mean change in CMT was similar
(e168215 mm vs. -110171 mm; P ¼ 0.132). Time to 15-letter
improvement from baseline, time to 10-letter improvement from
baseline, time to 10-letter reduction from baseline, time to 15-letter
reduction from baseline, time to peak improvement in BCVA from
baseline, time to peak improvement in CMT from baseline, number
of injections, and duration in study did not differ significantly
between controlled and uncontrolled diabetes patients. Further
comparisons and details are described in Table S1C (available at
www.aaojournal.org).
Rescue Therapy
Our study permitted rescue therapy to be given at the physician’s
discretion. In the per-injection analysis, rescue therapy was given
within 6months of follow-up in 61 (8.0%) of the 762 injections. This
treatment was administered, on average, 83.939.4 days after the
dexamethasone intravitreal implant injection. No eye received more
than 1 rescue treatment within the 6 months after an injection. In the
injection series analysis, of 171 eyes, 32 (18.7%) received rescue
therapy at 1 or more points throughout the entire series, with an
overall of 44 treatments administered. This treatment was adminis-
tered on average 86.844.5 days after the dexamethasoneintravitreal implant injection. Further description of the different
rescue treatments given is presented in Table S2 (available at
www.aaojournal.org).
Safety Outcomes
Throughout the study, no cases of endophthalmitis or retinal
detachment were reported, and the percentage of IOP-related AE
was relatively low, with 52 injections (6.8%) resulting in an in-
crease of IOP of more than 10 mmHg and 7 injections (0.9%)
resulting in a final IOP of more than 35 mmHg. No serious AEs
were reported (Table 6).Discussion
In this large, multicenter, real-life study, multiple anatomic
and functional parameters measuring the efficacy of dexa-
methasone implant in 2 different perspectives were assessed.
The response to each injection was assessed, and pharmaco-
dynamics, efficacy, and safety were analyzed. In addition, the
final outcome after a series of injections was assessed in a
similar fashion to that in the pivotal MEAD trial.16 However,
rather than limiting the interval to a strict 6-month period, all
intervals ranging from 3 to 6 months were included. The9

















Baseline BCVA (ETDRS letters), mean  SD 61.913.5 65.012.6 62.012.4 55.117.6 2.9519 0.7798 to 5.1240 0.0078
Injections with 15-letter BCVA improvement
from baseline, no. (%)
173 (22.7) 52 (26.5) 93 (20.0) 28 (28.0) 0.6905 0.4674 to 1.0199 0.0619
Time to 15-letter improvement in BCVA from
baseline (days), mean  SD
81.339.2 86.838.0 79.238.6 78.443.8 7.5780 e5.5629 to 20.7188 0.2562
Injections with 10-letter BCVA improvement
from baseline, no. (%)
288 (37.8) 93 (47.4) 158 (33.9) 37 (37.0) 0.5681 0.4045 to 0.7980 0.0010
Time to 10-letter improvement in BCVA from
baseline (days), mean  SD
79.938.5 84.137.2 77.938.6 78.041.6 6.2366 e3.5703 to 16.0436 0.2116
Injections with 10-letter BCVA reduction from
baseline, no. (%)
95 (12.5) 16 (8.2) 63 (13.5) 16 (16.0) 1.8878 1.0596 to 3.3634 0.0289
Time to 10-letter reduction in BCVA change
from baseline (days), letters, mean  SD
96.644.3 88.147.5 10143.2 89.145.9 e12.5575 e37.1090 to 11.9940 0.3116
Injections with 15-letter BCVA reduction from
baseline at study end, no. (%)
58 (7.6) 11 (5.6) 33 (7.1) 14 (14.0) 1.3671 0.6756 to 2.7661 0.3829
Time to 15-letter reduction in BCVA change
from baseline (days), letters, mean  SD
96.545.3 83.953.0 10441.5 87.747.2 e20.4848 e51.7798 to 10.8101 0.1937
Change in BCVA from baseline (ETDRS letters),
mean  SD
6.811.1 7.411.1 6.611.0 6.711.7 0.8265 e1.2664 to 2.9194 0.4382
Time to peak improvement in BCVA from baseline
(ETDRS letters), mean  SD
81.939.7 85.140.7 80.938.7 80.442.5 4.2340 e3.1974 to 11.6653 0.2635
Baseline CMT (mm), mean  SD 498139 494147 502141 490116 e8.6163 e46.6244 to 29.3917 0.6556
Change in CMT from baseline at study end (mm),
mean  SD
e174171 e151171 e180173 e193158 29.0965 e4.4305 to 62.6235 0.0888
Time to peak improvement in CMT from baseline
(days), mean  SD
79.638.1 87.041.7 76.534.8 79.943.8 10.5026 2.9670e18.0382 0.0065
No. of injections, mean  SD 2.11.2 2.11.3 2.11.2 2.11.1 e0.0213 e0.2247 to 0.1820 0.8369
Duration (yrs) in study, mean  SD 1.80.8 1.90.8 1.70.8 2.00.9 0.1469 e0.0624 to 0.3562 0.1681
BCVA ¼ best-corrected visual acuity; CMT ¼ central macular thickness; ETDRS ¼ Early Treatment Diabetic Retinopathy Study; SD ¼ standard deviation.


















Figure 5. Graph showing anatomic changes after a dexamethasone implant injection, stratified by diabetic macular edema (DME) duration (per-injection
analysis). CMT ¼ central macular thickness; SE ¼ standard error.
Rosenblatt et al  The ARTES Studyoutcome was compared within the entire cohort and between
treatment-naive and previously treated eyes, patients with
early and late duration of DME, and patients with controlled
and uncontrolled diabetes. To the best of our knowledge, this
is one of the largest and more comprehensive real-life study
assessing the efficacy of the dexamethasone intravitreal
implant in a defined injection series setting across multiple
subgroups and the only study applying the per-injection
analysis to understand better the pharmacodynamics of the
dexamethasone intravitreal implant.
This study showed that one quarter of injections in the
per-injection analysis and one fifth of the injection series
resulted in BCVA improvement of 15 ETDRS letters or
more. More than one third of the injections in both the per-
injection analysis and in the injection series analysis resulted
in BCVA improvement of 10 ETDRS letters or more. The
similar outcome of the per-injection and the injection series
analysis highlights the repeatability of the dexamethasone
intravitreal implant effect.
These results are in concordance with the MEAD 3-year
results,16 in which 22.2% of patients in the dexamethasone
intravitreal implant 0.7-mg group gained 15 ETDRS letters
or more. Other real-life postmarketing studies evaluating the
outcome of an injection series demonstrated variable results
with 15-letter gains occurring in 14% to 36% ofpatients.24e27 This may be attributed to the variability in the
definition of both the outcomes and the actual series. Unlike
the current study, in which the interval between injections
was set to 3 to 6 months, most real-life studies did not limit
the interval between injections, with reported treatment in-
tervals ranging up to 23 months.17,24,26,28 Thus, the actual
effect of the drug may be hindered by additional rescue
treatments and the cumulative effect potentially lost, in
turn rendering the definition of a series somewhat
obsolete. Looking at the treatment effect over time within
an injection series, this study demonstrated a pendular
effect profile of improvement and deterioration in both
visual acuity and anatomic outcome. This was expected
and demonstrated previously in the MEAD trials.16 The
MEAD study protocol dictated a dexamethasone injection
every 6 months with 3 months between observations. This
may have hindered the ability to characterize the pendular
effect accurately and to evaluate the time frame of the
drugs’ effectiveness. In a real-life setting, this effect also
is difficult to characterize because of the variable interval
between injections, hence, the significance of applying the
per-injection analysis implemented in this study, which
allowed better understanding of the effect after each injec-
tion, regardless of previous or subsequent injections, over-
lapping treatment intervals, or both. The per-injection11
Figure 6. Graph showing functional changes after a dexamethasone implant injection, stratified by diabetic macular edema (DME) duration (per-injection
analysis). ETDRS ¼ Early Treatment Diabetic Retinopathy Study; SE ¼ standard error.
Ophthalmology Volume -, Number -, Month 2019analysis demonstrated a rapid anatomic improvement that
was sustained until achieving a maximum effect 3 months
after injection. Thereafter, the effect deteriorated but did not
return to baseline. Change in visual acuity followed similar
dynamics but lagged after the anatomic improvement. The
PLACID,29 Mozart,30 and a few small real-life
studies17,31,32 analyzed the outcome of a single
dexamethasone injection and demonstrated similar
pendular characteristics with some lingering effect.
Furthermore, it is interesting to note the similarities of the
single-injection trial results with the per-injection analysis
of the present study, validating this analysis and re-
emphasizing the repeatability of the dexamethasone intra-
vitreal implant effect. Therefore, contrary to trials advo-
cating for reinjection of the dexamethasone intravitreal
implant with 6-month intervals, it is safe to conclude that
shorter treatment intervals are reasonable.
Throughout the current study, the percentage of patients
experiencing BCVA deterioration was relatively small.16,32
Safety-related outcomes and percentage of IOP-related
AEs were lower than in the MEAD trial, with no endoph-
thalmitis reported. Although the relatively small percentage
of patients with elevated IOP is not surprising, the nature of
this retrospective real-life study design always warrants12some considerations as to the potential presence of report
bias, mainly because real-life medical files may lack the
detailed and strict follow-up of a randomized control trial.
In the current study, both treatment-naive and previously
treated eyes showed a significant anatomic response and
significant visual acuity improvement, as reported in the
subgroup analysis of the MEAD trial.33 Improvement was
more pronounced in treatment-naive eyes compared with
previously treated eyes. These results are in concordance
with several other real-life studies,26,28,32e34 indicating a
more favorable visual outcome in treatment-naive compared
with previously treated eyes. Iglicki et al28 associated
previously treated patients with longer and more refractory
edema and consequently, a disruption in the inner
segmenteouter segment layer. Because this assumption
seems valid, the analysis of these anatomic changes was not
within the scope of this study. However, the present study
did examine the difference between early and late DME, and
in this analysis, both groups showed good functional and
anatomic outcomes, and the differences between groups
were even more pronounced than the differences between
treatment-naive and previously treated patients. All visual
outcomes were worse in eyes with longstanding DME, thus
making the duration of DME an important predictor for























Baseline BCVA (ETDRS letters), mean  SD 61.913.5 63.612.1 60.615.2 59.113.5 2.9436 0.5978 to 5.2894 0.0140
Injections with 15-letter BCVA improvement
from baseline, no. (%)
173 (22.7) 94 (24.4) 50 (20.2) 29 (22.7) 0.7844 0.5324 to 1.1559 0.2190
Time to 15-letter improvement in BCVA from
baseline (days), mean  SD
81.339.2 77.036.1 86.543.1 86.341.7 e9.5187 e22.8918 to 3.8543 0.1616
Injections with 10-letter BCVA improvement
from baseline, no. (%)
288 (37.8) 152 (39.4) 88 (35.5) 48 (37.5) 0.8467 0.6083 to 1.1786 0.3238
Time to 10-letter improvement in BCVA from
baseline (days), mean  SD
79.938.5 76.536.5 85.241.6 81.238.8 e8.7016 e18.8381 to 1.4349 0.0921
Injections with 10-letter BCVA reduction from
baseline, no. (%)
95 (12.5) 39 (10.1) 40 (16.1) 16 (12.5) 1.7254 1.0721 to 2.7769 0.0235
Time to 10-letter reduction in BCVA change
from baseline (days), letters, mean  SD
96.644.3 95.841.2 95.144.0 10253.8 0.6699 e18.4368 to 19.7766 0.9445
Injections with 15-letter BCVA reduction from
baseline at study end, no. (%)
58 (7.6) 22 (5.7) 26 (10.5) 10 (7.8) 1.9506 1.0774 to 3.5313 0.0252
Time to 15-letter reduction in BCVA change
from baseline (days), letters, mean  SD
96.545.3 10043.3 92.845.6 97.752.7 7.5490 e18.4406 to 33.5385 0.5616
Change in BCVA from baseline (ETDRS letters),
mean  SD
6.811.1 7.511.4 5.811.0 6.710.4 1.7119 e0.3330 to 3.7567 0.1006
Time to peak improvement in BCVA from baseline
(days), mean  SD
81.939.7 79.338.2 84.940.3 84.543.2 e5.5117 e12.5826 to 1.5593 0.1263
Baseline CMT (mm), mean  SD 498139 502148 478118 526145 23.3925 e11.0365 to 57.8215 0.1819
Change in CMT from baseline at study end (mm),
mean  SD
e174171 e190178 e135145 e204183 e54.9981 e84.1418 to e25.8544 0.0002
Time to peak improvement in CMT from baseline
(days), mean  SD
79.638.1 79.937.7 79.737.9 78.339.8 0.2500 e6.5284 to 7.0285 0.9423
No. of injections, mean  SD 2.11.2 2.11.2 2.21.3 2.21.2 e0.0890 e0.2801 to 0.1020 0.3605
Duration (yrs) in study, mean  SD 1.80.8 1.80.8 1.90.9 1.70.8 0.1469 e0.0624 to 0.3562 0.1681
BCVA ¼ bestecorrected visual acuity; CMT ¼ central macular thickness; ETDRS ¼ Early Treatment Diabetic Retinopathy Study; SD ¼ standard deviation.














Figure 7. Graph showing anatomic changes after a dexamethasone implant injection, stratified by diabetic control (per-injection analysis). CMT ¼ central
macular thickness; DM ¼ diabetes mellitus; HbA1c ¼ hemoglobin A1c; SE ¼ standard error.
Ophthalmology Volume -, Number -, Month 2019visual outcomes. A subgroup analysis of the MEAD study
published by Augustin et al33 concluded that the
dexamethasone intravitreal implant significantly improves
visual and anatomic outcomes in patients who previously
received intravitreal anti-VEGF or triamcinolone injections
or laser treatment. Our study adds new data and emphasizes
that results may be even better in early DME (of less than 6
months’ duration) in both treatment-naive and previously
treated eyes. Cunha-Vaz et al35 showed the long-term
benefit of sustained-delivery fluocinolone acetonide im-
plants in patients with chronic DME (3 years), which was
explained by the multifactorial pharmacologic profile of the
drug. We hypothesize that the difference between the
studies’ results may be that a chronic prolonged DME may
respond better to a low continuous dose of fluocinolone,
whereas early DME may benefit from an ad hoc dosing.
Uncontrolled diabetes was defined in the current study
similarly to how it was defined in the MEAD trial, as
HbA1c of more than 8 mg/100, and these patients showed
both worse baseline BCVA and a higher risk of losing
visual acuity, but no difference was found in the percent-
age of patients gaining visual acuity or in anatomic out-
comes. We hypothesize that this indicates that the
dexamethasone intravitreal implant is efficient for all pa-
tients regardless of systemic diabetic control and that both14initial and final lower BCVA may be associated with
diabetes complications such as vitreous hemorrhage or
recurrent DME, which are more common in uncontrolled
diabetes.36,37
Our study was not without limitations, which derive
mainly from its real-life retrospective multicenter aspect. As
such, patients varied widely with different baseline charac-
teristics and different ocular histories, contrary to random-
ized control trails. Visual acuity was extrapolated from
Snellen VA to EDTRS letters; thus, mean letter gains and
losses may not be as accurate as in clinical trials in which
VA is measured in EDTRS letters initially. Additionally, our
study applied certain exclusion criteria regarding glaucoma
patients, as such allowing IOP elevation to be higher in a
cohort that did not strictly exclude eyes with glaucoma or
ocular hypertension.
Additionally, some patients with serious AEs and
perhaps AEs may be unintentionally underrepresented in
the injection series analysis because of discontinuation of
sequential injections. However, the evaluation of serious
AEs and AEs of these patients are represented in the per-
injection analysis. Furthermore, unlike randomized control
trials and single-injection studies, patients included in our
study were treated in different centers with different follow-
up schedules and different treatment strategies, giving a
Figure 8. Graph showing functional changes after a dexamethasone implant injection, stratified by diabetic control (per-injection analysis). DM ¼ diabetes
mellitus; ETDRS ¼ Early Treatment Diabetic Retinopathy Study; HbA1c ¼ hemoglobin A1c; SE ¼ standard error.










25 5 (2.9) 60 (7.9)
35 1 (0.6) 7 (0.9)
Increase of 10 mmHg
from baseline
2 (1.2) 52 (6.8)
Use of IOP-lowering
medication
28 (6.3) 48 (6.3)
Cataract* 32 (18.7) 44 (12.9)
Cataract operation* 31 (18.1) 42 (12.4)
Vitreous hemorrhage 3 (0.6) 3 (0.4)
Retinal detachments 0 (0) 0 (0)
Endophthalmitis 0 (0) 0 (0)
Other related adverse
events
76 (17.1) 112 (14.7)
IOP ¼ intraocular pressure.
Data are no. (%).
*Percentage is per eye, not per injection. All other percentages based on
the number of injections.
Rosenblatt et al  The ARTES Studymore heterogenic population. Thus, some results could be
masked by relatively large heterogenicity between patients,
as seen in the injection series analysis, and the potential
exists for the presence of unaccounted-for biases. Finally,
anatomic outcome was limited to CMT, with no further
analysis of the OCT images. Nevertheless, in this large,
international multicenter real-life study, the intravitreal
dexamethasone implant proved to be effective and safe in
treatment-naive and previously treated eyes, eyes with early
and late DME, and patients with controlled and uncon-
trolled diabetes. Peak improvement was achieved approxi-
mately 3 months after injection in all groups and dissipated
thereafter.
In conclusion, our study demonstrates the benefit of
dexamethasone intravitreal implant treatment in various
subgroups of patients with DME with a relatively low
incidence of AEs, including IOP elevation and cataract
formation. It is our belief that the dexamethasone implant
may be considered as a viable treatment option for a wide
array of DME patients. Clinicians and providers should
consider shortening treatment intervals or as-needed treat-
ment regimens to maintain and maximize a beneficial
clinical effect.15
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